Equities

Joinn Laboratories China Co Ltd

Joinn Laboratories China Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)13.65
  • Today's Change-0.37 / -2.64%
  • Shares traded10.62m
  • 1 Year change-41.24%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments4,7603,3084,831
Total Receivables, Net368358232
Total Inventory1,8632,195701
Prepaid expenses1215047
Other current assets, total9.26173.70
Total current assets7,1225,9285,814
Property, plant & equipment, net1,5761,779849
Goodwill, net136134122
Intangibles, net292300137
Long term investments7982,1461,536
Note receivable - long term------
Other long term assets0.140.252.98
Total assets10,02710,3648,537
LIABILITIES
Accounts payable4312754
Accrued expenses11313584
Notes payable/short-term debt000
Current portion long-term debt/capital leases272826
Other current liabilities, total1,2841,5551,051
Total current liabilities1,4671,8441,214
Total long term debt426069
Total debt698895
Deferred income tax16218848
Minority interest1.727.168.22
Other liabilities, total748161
Total liabilities1,7482,1811,401
SHAREHOLDERS EQUITY
Common stock750536381
Additional paid-in capital5,2675,4805,544
Retained earnings (accumulated deficit)2,3082,1251,189
Treasury stock - common(146)(53)(3.93)
Unrealized gain (loss)939247
Other equity, total7.153.15(21)
Total equity8,2798,1847,136
Total liabilities & shareholders' equity10,02710,3648,537
Total common shares outstanding744749746
Treasury shares - common primary issue6.260.720.91
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.